Spyre Therapeutics Overview
- Year Founded
-
2023

- Status
-
Public
- Employees
-
60

- Stock Symbol
-
SYRE

- Investments
-
1
- Share Price
-
$22.92
- (As of Friday Closing)
Spyre Therapeutics General Information
Description
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Contact Information
Website
www.spyre.comCorporate Office
- 221 Crescent Street
- Suite 105
- Waltham, MA 02453
- United States
Corporate Office
- 221 Crescent Street
- Suite 105
- Waltham, MA 02453
- United States
Spyre Therapeutics Timeline
Spyre Therapeutics Stock Performance
As of 14-Feb-2025, Spyre Therapeutics’s stock price is $22.92. Its current market cap is $1.38B with 60.3M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$22.92 | $22.68 | $20.07 - $47.97 | $1.38B | 60.3M | 609K | -$1.50 |
Spyre Therapeutics Financials Summary
As of 30-Sep-2024, Spyre Therapeutics has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 1,227,374 | 958,678 | (41,256) | 127,003 |
Revenue | 0 | 886 | 2,329 | 18,739 |
EBITDA | (234,514) | (344,219) | (83,221) | (64,195) |
Net Income | (214,902) | (338,790) | (83,815) | (65,801) |
Total Assets | 421,089 | 341,859 | 71,144 | 109,926 |
Total Debt | 0 | 0 | 4,629 | 5,060 |
Spyre Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Spyre Therapeutics Comparisons
Industry
Financing
Details
Spyre Therapeutics Competitors (66)
One of Spyre Therapeutics’s 66 competitors is Codiak BioSciences, a Formerly VC-backed company based in Cambridge, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Codiak BioSciences | Formerly VC-backed | Cambridge, MA | ||||
Mesoblast | Corporation | Melbourne, Australia | ||||
Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
Artizan Biosciences | Venture Capital-Backed | New Haven, CT | ||||
AnTolRx | Venture Capital-Backed | Cambridge, MA |
Spyre Therapeutics Patents
Spyre Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20110200576-A1 | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof | Active | 04-Feb-2010 | ||
US-8709407-B2 | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof | Active | 04-Feb-2010 | ||
US-8679479-B2 | Methods for purifying pegylated arginase | Active | 29-Jun-2009 | ||
US-20120177628-A1 | Arginase formulations and methods | Active | 29-Jun-2009 | ||
US-9050340-B2 | Compositions of engineered human arginases and methods for treating cancer | Active | 31-Oct-2008 | A61K38/50 |
Spyre Therapeutics Signals
Spyre Therapeutics Acquisitions (1)
Spyre Therapeutics’s most recent deal was a Merger/Acquisition with Aeglea BioTherapeutics. The deal was made on 22-Jun-2023.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Aeglea BioTherapeutics | 22-Jun-2023 | Merger/Acquisition | Drug Discovery |
Spyre Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
34.16 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile

Pharmaceuticals
Industry
of 965
Rank
Percentile

Biotechnology
Subindustry
of 443
Rank
Percentile

Spyre Therapeutics FAQs
-
When was Spyre Therapeutics founded?
Spyre Therapeutics was founded in 2023.
-
Where is Spyre Therapeutics headquartered?
Spyre Therapeutics is headquartered in Waltham, MA.
-
What is the size of Spyre Therapeutics?
Spyre Therapeutics has 60 total employees.
-
What industry is Spyre Therapeutics in?
Spyre Therapeutics’s primary industry is Drug Discovery.
-
Is Spyre Therapeutics a private or public company?
Spyre Therapeutics is a Public company.
-
What is Spyre Therapeutics’s stock symbol?
The ticker symbol for Spyre Therapeutics is SYRE.
-
What is the current stock price of Spyre Therapeutics?
As of 14-Feb-2025 the stock price of Spyre Therapeutics is $22.92.
-
What is the current market cap of Spyre Therapeutics?
The current market capitalization of Spyre Therapeutics is $1.38B.
-
Who are Spyre Therapeutics’s competitors?
Codiak BioSciences, Mesoblast, Rhythm Pharmaceuticals, Artizan Biosciences, and AnTolRx are some of the 66 competitors of Spyre Therapeutics.
-
What is Spyre Therapeutics’s annual earnings per share (EPS)?
Spyre Therapeutics’s EPS for 12 months was -$1.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »